Fluoroquinolones

To divide, a bacterium must copy its circular chromosome — but that long DNA is tightly coiled and would tangle without help. Two enzymes manage it: DNA gyrase (topoisomerase II) relieves the supercoiling ahead of the replication fork, and topoisomerase IV separates the two daughter chromosomes afterward. Both work by making a controlled cut in the DNA and resealing it. Fluoroquinolones jam that process: they trap the enzyme-DNA complex mid-cut, converting a routine repair into permanent double-stranded breaks in the chromosome.

The result is catastrophic and irreversible for the cell — DNA replication halts and the bacterium dies, making these drugs bactericidal. Because they target enzymes essential to a huge range of organisms, fluoroquinolones are broad-spectrum and orally well-absorbed with excellent tissue penetration — genuinely useful drugs for complicated UTIs, certain pneumonias (the "respiratory" quinolones levofloxacin and moxifloxacin), and intra-abdominal or resistant infections. The problem, as the next section shows, is not efficacy — it is toxicity.

Fluoroquinolones carry one of the most consequential boxed warnings in the pharmacy, because they can cause disabling and potentially irreversible reactions that tend to occur together. Tendinitis and tendon rupture (classically the Achilles, often bilateral) can strike even after the course ends, with higher risk over age 60, on corticosteroids, and in transplant recipients. Peripheral neuropathy — numbness, tingling, burning weakness — may be permanent. Central nervous system effects range from insomnia and dizziness to confusion and seizures (GABA-A antagonism lowers the seizure threshold). And they can exacerbate myasthenia gravis to the point of respiratory failure — so they are avoided in MG entirely.

Because these harms can be severe and lasting, the FDA added a "limitation of use": reserve fluoroquinolones for patients who have no better alternative for acute sinusitis, acute bronchitis, and uncomplicated UTI — common infections where the risk outweighs the benefit. Later safety communications added more: an increased risk of aortic aneurysm and dissection (avoid in patients with or at risk for aneurysm), blood-sugar disturbances including severe hypoglycemia (especially with sulfonylureas), and mental-health effects (delirium, agitation, memory problems). They also prolong the QT (most with moxifloxacin). The nursing takeaway is a reflex: question a fluoroquinolone order for a minor infection, and know the red flags to stop the drug.

Two everyday interaction patterns matter enormously. First, cations chelate the drug: taken with calcium, magnesium, aluminum antacids, iron, zinc, dairy, or sucralfate, a fluoroquinolone binds those metal ions in the gut and its absorption plummets (up to ~90%) — so oral doses are separated from these products (e.g., ciprofloxacin 2 hours before or 6 hours after). This is a classic exam point and a real cause of treatment failure. Second, they raise bleeding and toxicity risks with specific drugs: warfarin (rising INR — monitor closely), and theophylline/caffeine/tizanidine via CYP1A2 inhibition (ciprofloxacin), which can push theophylline to seizures — indeed ciprofloxacin plus tizanidine is contraindicated.

Layered on top are additive dangers: QT-prolonging drugs and low potassium/magnesium raise the torsades risk, corticosteroids amplify tendon rupture, and antidiabetic drugs compound the dysglycemia. Practical nursing follows directly: space the cations, check the INR, monitor glucose (especially in diabetics), protect against photosensitivity, keep the patient hydrated (to prevent crystalluria), and teach the patient to stop the drug and call at the first tendon pain, new numbness/tingling, or palpitations.